论文部分内容阅读
胰岛细胞的移植是最有希望治疗糖尿病的方法之一,近年来研究取得了一些进展,但供体缺乏和免疫排斥仍是限制其发展的两大难题。骨髓间充质干细胞(BM-MSCs)在体外可通过多种方法诱导分化为胰岛样分泌细胞,为细胞移植治疗糖尿病提供了新的思路与方法。近年来,干细胞理论和实验技术得到了进一步发展,通过自体移植同时避免了供体缺乏和免疫排斥两大难题。利用干细胞治疗糖尿病成为临床上最近研究的热点。该文对间充质干细胞向胰岛样细胞分化诱导的现状及研究进展作一综述。
Transplantation of islet cells is one of the most promising ways to treat diabetes. Some progress has been made in recent years, but donor deficiencies and immune rejection are still two major problems that limit their development. Bone marrow-derived mesenchymal stem cells (BM-MSCs) can be differentiated into pancreatic islet-like secretory cells in vitro by a variety of methods, providing new ideas and methods for cell transplantation in the treatment of diabetes. In recent years, stem cell theory and experimental techniques have been further developed. At the same time, autologous transplantation avoids the two major problems of donor deficiency and immune rejection. The use of stem cells for the treatment of diabetes has become a hot spot in recent clinical studies. This article reviews the current situation and progress of differentiation induction of mesenchymal stem cells into islet-like cells.